代谢驱动预后模型与PSMD14-SP1-GYS1轴揭示黑色素瘤治疗弱点
该研究整合多组学数据与机器学习,基于114条代谢相关通路构建黑色素瘤代谢相关预后模型(MRPM),在4个队列中验证其预测准确性。高风险患者生存更差且免疫治疗反应不佳。机制上GYS1为关键预后基因,SP1转录调控GYS1,PSMD14通过去除K48连接泛素化稳定SP1,体内验证PSMD14敲低经SP1-GYS1轴抑制肿瘤生长。
要点
- MRPM高风险黑色素瘤患者生存更差且免疫治疗反应不佳
- GYS1是MRPM关键基因,促进黑色素瘤增殖和转移
- PSMD14-SP1-GYS1轴是潜在代谢治疗靶点
核心结论
- MRPM是稳健的预测工具,PSMD14-SP1-GYS1调控网络是黑色素瘤代谢的潜在治疗靶点。
研究设计与样本
- 研究整合TCGA、GEO和ENA多组学数据,聚焦114条代谢相关通路。
- 使用101种机器学习算法组合构建MRPM,并在4个队列中验证预测准确性。
主要发现
- Cox回归识别70个与生存相关的基因,功能富集揭示关键代谢通路改变。
- 高风险患者生存更差且免疫治疗反应不佳,涉及黑色素瘤及其他癌症。
- 肿瘤微环境分析显示MRPM与免疫浸润负相关、与肿瘤纯度正相关。
- 单细胞测序显示MRPM基因在黑色素细胞中富集。
- GYS1促进黑色素瘤增殖和转移,SP1转录调控GYS1,PSMD14通过去除K48连接泛素化稳定SP1。
临床怎么用
- MRPM可用于黑色素瘤预后预测和免疫治疗反应评估。
- PSMD14-SP1-GYS1轴可作为代谢治疗靶点进行进一步开发。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Melanoma is a highly aggressive cutaneous malignancy characterized by a strong propensity for metastasis and therapy resistance, with its progression being closely linked to metabolic reprogramming. This study integrated multiomics data (The Cancer Genome Atlas, Gene Expression Omnibus, European Nucleotide Archive) and advanced machine learning to develop prognostic and immunotherapy prediction models for melanoma, focusing on 114 metabolism-related pathways. Cox regression identified 70 genes linked to survival, with functional enrichment revealing key metabolic pathway alterations. A metabolism-related prognostic model (MRPM) was constructed using 101 combinations of machine learning algorithms, demonstrating superior predictive accuracy across 4 cohorts. High-risk patients showed worse survival and immunotherapy response in melanoma and other cancers. Tumor microenvironment analysis revealed MRPM's negative correlation with immune infiltration and positive association with tumor purity. Single-cell sequencing highlighted MRPM gene enrichment in melanocytes. Mechanistically, GYS1 (the key gene in MRPM) emerged as a pivotal prognostic gene that promotes melanoma proliferation and metastasis. Regulatory studies uncovered SP1's transcriptional control of GYS1- and PSMD14-mediated stabilization of SP1 through K48-linked ubiquitination removal. In vivo validation confirmed that PSMD14 knockdown suppressed tumor growth through SP1-GYS1 axis disruption. This work establishes MRPM as a robust predictive tool and elucidates the PSMD14-SP1-GYS1 regulatory network as a potential therapeutic target in melanoma metabolism.
引用
- Xie J, Zhao S, Wu D, et al. A Metabolism-Driven Prognostic Model and PSMD14-SP1-GYS1 Axis Reveal Therapeutic Vulnerabilities in Melanoma. J Invest Dermatol. 2025. PMID: 40967300. doi:10.1016/j.jid.2025.08.044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。